[P02BB01, trichlorfon, Metrifonate may increase the neuromuscular blocking activities of Irinotecan.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Irinotecan.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Irinotecan.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Irinotecan.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Irinotecan.]
[L04AA27, fingolimod, Irinotecan may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The serum concentration of Irinotecan can be increased when it is combined with Succinylcholine.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Irinotecan.]
[M04AB02, sulfinpyrazone, The metabolism of Irinotecan can be increased when combined with Sulfinpyrazone.]
[N05AL01, sulpiride, Sulpiride may increase the neuromuscular blocking activities of Irinotecan.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Mercaptopurine.]
[N06DA01, tacrine, Tacrine may increase the neuromuscular blocking activities of Irinotecan.]
[L02BA01, tamoxifen, The metabolism of Irinotecan can be increased when combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Irinotecan can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Terbutaline may increase the neuromuscular blocking activities of Irinotecan.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Irinotecan.]
[G03BA03, testosterone, The metabolism of Irinotecan can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Irinotecan can be decreased when combined with Tetracycline.]
[A04AD10, dronabinol, The metabolism of Irinotecan can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The metabolism of Irinotecan can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Irinotecan is combined with Thalidomide.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Irinotecan is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Irinotecan is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Irinotecan.]
[B02AB01, aprotinin, Aprotinin may increase the neuromuscular blocking activities of Irinotecan.]
[G04BE06, moxisylyte, The serum concentration of Moxisylyte can be increased when it is combined with Irinotecan.]
[B01AC05, ticlopidine, The metabolism of Irinotecan can be decreased when combined with Ticlopidine.]
[N02AX02, tramadol, The metabolism of Irinotecan can be decreased when combined with Tramadol.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Irinotecan.]
[N06AX05, trazodone, The metabolism of Irinotecan can be decreased when combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Irinotecan.]
[S01BA05, triamcinolone, The metabolism of Irinotecan can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, The metabolism of Triazolam can be decreased when combined with Irinotecan.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Irinotecan.]
[S01EB04, demecarium, Demecarium may increase the neuromuscular blocking activities of Irinotecan.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Irinotecan.]
[N05AA05, triflupromazine, Triflupromazine may increase the neuromuscular blocking activities of Irinotecan.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Irinotecan is combined with Fluclorolone.]
[R03BA07, mometasone, The metabolism of Irinotecan can be increased when combined with Mometasone.]
[C02BA01, trimethaphan, The serum concentration of Trimethaphan can be increased when it is combined with Irinotecan.]
[J01FA08, troleandomycin, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Troleandomycin.]
[M03AA02, tubocurarine, Tubocurarine may increase the neuromuscular blocking activities of Irinotecan.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Irinotecan.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Belimumab.]
[S01AA05, tyrothricin, Tyrothricin may increase the neuromuscular blocking activities of Irinotecan.]
[L01EX04, vandetanib, Vandetanib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[A10BH05, linagliptin, The metabolism of Irinotecan can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Irinotecan can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Irinotecan.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Irinotecan is combined with Belatacept.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Irinotecan.]
[B01AC24, ticagrelor, The metabolism of Irinotecan can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Irinotecan can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Irinotecan can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Irinotecan can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Irinotecan.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Irinotecan.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Irinotecan.]
[A11HA03, vitamin E, The metabolism of Irinotecan can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Irinotecan can be increased when combined with Warfarin.]
[S01AA13, fusidic acid, The metabolism of Irinotecan can be decreased when combined with Fusidic acid.]
[J05AF01, zidovudine, The metabolism of Irinotecan can be increased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Irinotecan can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Irinotecan can be increased when combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Irinotecan can be decreased when combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Irinotecan can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Irinotecan.]
[R03DC01, zafirlukast, The metabolism of Irinotecan can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[N05AE04, ziprasidone, The metabolism of Irinotecan can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Irinotecan can be decreased when combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Irinotecan.]
[N02BA01, aspirin, The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Irinotecan.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Irinotecan.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Irinotecan.]
[J02AC03, voriconazole, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Voriconazole.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Irinotecan.]
[R07AX02, ivacaftor, The metabolism of Irinotecan can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Irinotecan can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Irinotecan.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Irinotecan.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Irinotecan.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Irinotecan.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Irinotecan.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Irinotecan.]
[G04BD12, mirabegron, The serum concentration of Mirabegron can be increased when it is combined with Irinotecan.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Irinotecan is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Elvitegravir.]
[L02BB04, enzalutamide, The metabolism of Irinotecan can be increased when combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Irinotecan can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Irinotecan is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Irinotecan.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Irinotecan is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Irinotecan is combined with Aldosterone.]
[L01EX05, regorafenib, The risk or severity of neutropenia can be increased when Regorafenib is combined with Irinotecan.]
[N05CA04, barbital, The metabolism of Irinotecan can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Bendamustine.]
[C08CA13, lercanidipine, The metabolism of Irinotecan can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, Donepezil may increase the neuromuscular blocking activities of Irinotecan.]
[N03AX22, perampanel, The metabolism of Irinotecan can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, Irinotecan may increase the immunosuppressive activities of Tofacitinib.]
[H01CB05, pasireotide, The metabolism of Irinotecan can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Irinotecan can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Irinotecan.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Irinotecan.]
[C10AX12, lomitapide, The metabolism of Irinotecan can be decreased when combined with Lomitapide.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Irinotecan can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Irinotecan.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Irinotecan is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Irinotecan.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Irinotecan is combined with Dimethyl fumarate.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Benzocaine.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Irinotecan.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Irinotecan is combined with Everolimus.]
[L01EC02, dabrafenib, The risk or severity of neutropenia can be increased when Dabrafenib is combined with Irinotecan.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Benzyl alcohol.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L03AA14, lipegfilgrastim, Irinotecan may increase the myelosuppressive activities of Lipegfilgrastim.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Irinotecan.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Irinotecan.]
[N03AF04, eslicarbazepine, The metabolism of Irinotecan can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Irinotecan can be decreased when combined with Simeprevir.]
[N05CH03, tasimelteon, The metabolism of Irinotecan can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Irinotecan can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Irinotecan can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Irinotecan can be increased when combined with Formestane.]
[A16AA06, betaine, Betaine may increase the neuromuscular blocking activities of Irinotecan.]
[S03BA03, betamethasone, The metabolism of Irinotecan can be increased when combined with Betamethasone.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Irinotecan.]
[L04AC11, siltuximab, The metabolism of Irinotecan can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Irinotecan can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Irinotecan can be decreased when combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Acenocoumarol is combined with Irinotecan.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Irinotecan is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Irinotecan is combined with Idelalisib.]
[N07XX08, tafamidis, The serum concentration of Irinotecan can be increased when it is combined with Tafamidis.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Irinotecan is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Irinotecan can be decreased when combined with Suvorexant.]
[J01XA05, oritavancin, The metabolism of Irinotecan can be increased when combined with Oritavancin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Irinotecan is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Irinotecan can be decreased when combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Blinatumomab.]
[J05AP09, dasabuvir, The risk or severity of neutropenia can be increased when Dasabuvir is combined with Irinotecan.]
[L01XK01, olaparib, The metabolism of Irinotecan can be decreased when combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Dicoumarol is combined with Irinotecan.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Irinotecan.]
[N06AX11, mirtazapine, The metabolism of Irinotecan can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Irinotecan can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Irinotecan can be decreased when combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Irinotecan is combined with Panobinostat.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[N02BE01, acetaminophen, The metabolism of Irinotecan can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Irinotecan.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Irinotecan.]
[J05AP06, asunaprevir, The metabolism of Irinotecan can be increased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Irinotecan.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Irinotecan.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[S01EC01, acetazolamide, The metabolism of Irinotecan can be decreased when combined with Acetazolamide.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Irinotecan is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Irinotecan can be increased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Irinotecan can be decreased when combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The metabolism of Irinotecan can be decreased when combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Irinotecan can be decreased when combined with Cobimetinib.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[B01AC27, selexipag, The excretion of Selexipag can be decreased when combined with Irinotecan.]
[M04AB05, lesinurad, The metabolism of Irinotecan can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[N05CA05, aprobarbital, The metabolism of Irinotecan can be increased when combined with Aprobarbital.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Irinotecan.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Irinotecan can be decreased when combined with Venetoclax.]
[R06AB01, brompheniramine, The metabolism of Brompheniramine can be decreased when combined with Irinotecan.]
[N05AX17, pimavanserin, The metabolism of Irinotecan can be decreased when combined with Pimavanserin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Bupivacaine.]
[N07BC01, buprenorphine, The metabolism of Irinotecan can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, The metabolism of Irinotecan can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Irinotecan is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Rivastigmine may increase the neuromuscular blocking activities of Irinotecan.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Irinotecan.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Irinotecan.]
[L01XK03, rucaparib, The metabolism of Irinotecan can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Irinotecan can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Brodalumab.]
[L01EF02, ribociclib, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Ribociclib.]
[R03CC12, bambuterol, Bambuterol may increase the neuromuscular blocking activities of Irinotecan.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Irinotecan.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Irinotecan.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Irinotecan can be increased when combined with Calcitriol.]
[R05DB01, benzonatate, The serum concentration of Benzonatate can be increased when it is combined with Irinotecan.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Irinotecan.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Irinotecan.]
[J05AE09, tipranavir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Irinotecan.]
[L04AB02, infliximab, The metabolism of Irinotecan can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Midostaurin.]
[L01ED04, brigatinib, Brigatinib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L04AC14, sarilumab, The metabolism of Irinotecan can be increased when combined with Sarilumab.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Irinotecan.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Irinotecan can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Capecitabine.]
[L01XX59, enasidenib, The risk or severity of neutropenia can be increased when Enasidenib is combined with Irinotecan.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Irinotecan is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Irinotecan.]
[L01EF03, abemaciclib, Abemaciclib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[J05AG03, efavirenz, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Irinotecan.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Irinotecan.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Irinotecan.]
[R03BA02, budesonide, The metabolism of Irinotecan can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Irinotecan.]
[L01EL02, acalabrutinib, The metabolism of Irinotecan can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Irinotecan can be decreased when combined with Letermovir.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Capsaicin.]
[A10BK04, ertugliflozin, The risk or severity of neutropenia can be increased when Ertugliflozin is combined with Irinotecan.]
[L02BB05, apalutamide, The metabolism of Irinotecan can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Irinotecan can be increased when combined with Carbamazepine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Irinotecan.]
[B02BX09, fostamatinib, The risk or severity of neutropenia can be increased when Fostamatinib is combined with Irinotecan.]
[N03AX24, cannabidiol, The metabolism of Irinotecan can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Irinotecan is combined with Baricitinib.]
[H01CC03, elagolix, The excretion of Elagolix can be decreased when combined with Irinotecan.]
[L01XX62, ivosidenib, The metabolism of Irinotecan can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Irinotecan can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Irinotecan.]
[L01EM04, duvelisib, The metabolism of Irinotecan can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The risk or severity of neutropenia can be increased when Dacomitinib is combined with Irinotecan.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Chloroprocaine.]
[R03BB08, revefenacin, Irinotecan may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Irinotecan can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Irinotecan can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Irinotecan.]
[L01EX13, gilteritinib, The metabolism of Irinotecan can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, Glasdegib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ravulizumab.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Irinotecan.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Cilostazol is combined with Irinotecan.]
[P02BX04, triclabendazole, The metabolism of Irinotecan can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Irinotecan can be increased when combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Irinotecan is combined with Siponimod.]
[J01FA09, clarithromycin, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Clarithromycin.]
[N05BA09, clobazam, The metabolism of Irinotecan can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Irinotecan can be increased when combined with Cloprednol.]
[L04AB01, etanercept, The metabolism of Irinotecan can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Irinotecan can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Irinotecan can be increased when combined with Alpelisib.]
[L02BB06, darolutamide, Darolutamide may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L01EX15, pexidartinib, The risk or severity of neutropenia can be increased when Pexidartinib is combined with Irinotecan.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Irinotecan is combined with Upadacitinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[N07XX11, pitolisant, The serum concentration of Irinotecan can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Irinotecan can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Irinotecan can be increased when it is combined with Lefamulin.]
[N04CX01, istradefylline, Istradefylline may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Irinotecan.]
[J01DB01, cephalexin, The metabolism of Irinotecan can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Irinotecan can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Irinotecan can be increased when combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Irinotecan.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Irinotecan.]
[N02CC08, lasmiditan, The serum concentration of Irinotecan can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Irinotecan is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Irinotecan.]
[G03AC09, desogestrel, The metabolism of Irinotecan can be increased when combined with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Irinotecan can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Irinotecan can be decreased when it is combined with Cenobamate.]
[N05CM21, lemborexant, The serum concentration of Irinotecan can be decreased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Irinotecan can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Teprotumumab.]
[J05AB16, remdesivir, The metabolism of Irinotecan can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Irinotecan can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Irinotecan.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Irinotecan.]
[M01AH02, rofecoxib, The metabolism of Irinotecan can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Irinotecan can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Irinotecan can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Irinotecan can be decreased when combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Irinotecan can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Irinotecan.]
[S03AA08, chloramphenicol, The metabolism of Irinotecan can be decreased when combined with Chloramphenicol.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Irinotecan.]
[L01EX17, capmatinib, The serum concentration of Irinotecan can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Irinotecan can be increased when combined with Fluprednidene.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Irinotecan.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Irinotecan.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Irinotecan.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Irinotecan is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Irinotecan is combined with Stepronin.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be decreased when combined with Irinotecan.]
[R06AX22, ebastine, The metabolism of Irinotecan can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L01FX15, belantamab mafodotin, The excretion of Belantamab mafodotin can be decreased when combined with Irinotecan.]
[L04AC19, satralizumab, The serum concentration of Irinotecan can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Irinotecan can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Irinotecan can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Irinotecan.]
[R06AB04, chlorpheniramine, The metabolism of Chlorpheniramine can be decreased when combined with Irinotecan.]
[N05AA01, chlorpromazine, The metabolism of Irinotecan can be increased when combined with Chlorpromazine.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Irinotecan.]
[B06AC06, berotralstat, The serum concentration of Irinotecan can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Fludarabine.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Irinotecan.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Irinotecan is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Irinotecan can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, Tepotinib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[N03AX10, felbamate, The metabolism of Irinotecan can be increased when combined with Felbamate.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Irinotecan.]
[R03BA03, flunisolide, The metabolism of Irinotecan can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Irinotecan can be increased when combined with Fluocinolone acetonide.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ponesimod.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Irinotecan.]
[A02BA01, cimetidine, The metabolism of Irinotecan can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The metabolism of Irinotecan can be decreased when combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Irinotecan can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Irinotecan can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Irinotecan can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Irinotecan.]
[N06AB04, citalopram, The metabolism of Irinotecan can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Irinotecan is combined with Belumosudil.]
[P01CA03, fexinidazole, The metabolism of Irinotecan can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Irinotecan can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Irinotecan can be decreased when it is combined with Mobocertinib.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Irinotecan.]
[L04AA59, avacopan, The metabolism of Irinotecan can be decreased when combined with Avacopan.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Irinotecan.]
[N06AX25, St. John's wort extract, The metabolism of Irinotecan can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The risk or severity of neutropenia can be increased when Asciminib is combined with Irinotecan.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The metabolism of Irinotecan can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Irinotecan.]
[C10AB01, clofibrate, The metabolism of Irinotecan can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Irinotecan can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Irinotecan can be increased when it is combined with Pacritinib.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Irinotecan.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Irinotecan.]
[C01EB24, mavacamten, The serum concentration of Irinotecan can be decreased when it is combined with Mavacamten.]
[J02AC06, oteseconazole, The serum concentration of Irinotecan can be increased when it is combined with Oteseconazole.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Irinotecan.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Irinotecan is combined with Deucravacitinib.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Irinotecan.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Irinotecan.]
[J05AX31, lenacapavir, The metabolism of Irinotecan can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Irinotecan is combined with Clozapine.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Irinotecan can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Irinotecan can be increased when combined with Bimekizumab.]
[M03AC05, hexafluorenium, Hexafluronium may increase the neuromuscular blocking activities of Irinotecan.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Irinotecan is combined with Leflunomide.]
[A10BX03, nateglinide, The metabolism of Irinotecan can be decreased when combined with Nateglinide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Nelarabine.]
[J01FA15, telithromycin, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Irinotecan.]
[H01AX01, pegvisomant, Pegvisomant may increase the neuromuscular blocking activities of Irinotecan.]
[J02AC02, itraconazole, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Irinotecan.]
[N05BA10, ketazolam, The metabolism of Irinotecan can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Irinotecan can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Irinotecan.]
[N03AX09, lamotrigine, The metabolism of Irinotecan can be increased when combined with Lamotrigine.]
[S01BA03, cortisone, The metabolism of Irinotecan can be increased when combined with Cortisone.]
[C08CA11, manidipine, The metabolism of Irinotecan can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The metabolism of Irinotecan can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Irinotecan can be decreased when combined with Mequitazine.]
[C03DA04, eplerenone, The metabolism of Irinotecan can be decreased when combined with Eplerenone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Irinotecan.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Irinotecan.]
[J01FA03, midecamycin, The metabolism of Irinotecan can be decreased when combined with Midecamycin.]
[L01AA01, cyclophosphamide, The metabolism of Irinotecan can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, Minaprine may increase the neuromuscular blocking activities of Irinotecan.]
[S01XA18, cyclosporine, Irinotecan may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Irinotecan can be increased when combined with Modafinil.]
[C10AA07, rosuvastatin, The metabolism of Irinotecan can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Cytarabine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Irinotecan.]
[M01AH05, etoricoxib, The metabolism of Irinotecan can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Irinotecan is combined with Dactinomycin.]
[G03XA01, danazol, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Danazol.]
[J04BA02, dapsone, The metabolism of Irinotecan can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Irinotecan can be decreased when combined with Daunorubicin.]
[N06AX06, nefazodone, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Nefazodone.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Irinotecan.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Irinotecan.]
[N06AA01, desipramine, The metabolism of Irinotecan can be decreased when combined with Desipramine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Irinotecan.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Irinotecan.]
[N03AF02, oxcarbazepine, The metabolism of Irinotecan can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Irinotecan can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Irinotecan can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Irinotecan can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[R05DA09, dextromethorphan, The metabolism of Irinotecan can be decreased when combined with Dextromethorphan.]
[N06AB05, paroxetine, The metabolism of Irinotecan can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Irinotecan can be decreased when combined with Clopidogrel.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Irinotecan.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Irinotecan can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Irinotecan can be increased when combined with Dicloxacillin.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ixabepilone.]
[L01EB02, erlotinib, The risk or severity of neutropenia can be increased when Erlotinib is combined with Irinotecan.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Irinotecan is combined with Pirarubicin.]
[P02CB02, diethylcarbamazine, Diethylcarbamazine may increase the neuromuscular blocking activities of Irinotecan.]
[L02AA01, diethylstilbestrol, The metabolism of Irinotecan can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Irinotecan can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Irinotecan can be increased when combined with Difluocortolone.]
[N02BA11, diflunisal, The metabolism of Irinotecan can be decreased when combined with Diflunisal.]
[C01AA05, digoxin, The excretion of Digoxin can be decreased when combined with Irinotecan.]
[C10AX09, ezetimibe, The excretion of Ezetimibe can be decreased when combined with Irinotecan.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Irinotecan.]
[C04AE04, dihydroergocristine, The metabolism of Irinotecan can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Irinotecan can be decreased when combined with Dihydroergotamine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Irinotecan.]
[J05AE08, atazanavir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Irinotecan can be decreased when combined with Diltiazem.]
[M02AX03, dimethyl sulfoxide, The metabolism of Irinotecan can be decreased when combined with Dimethyl sulfoxide.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Irinotecan.]
[C05CA03, diosmin, The metabolism of Irinotecan can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Irinotecan can be decreased when combined with Quazepam.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Dipyridamole is combined with Irinotecan.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Irinotecan.]
[A03FA02, cisapride, The metabolism of Irinotecan can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Irinotecan.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Natalizumab.]
[N07AA03, distigmine, Distigmine may increase the neuromuscular blocking activities of Irinotecan.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be decreased when combined with Irinotecan.]
[S02AA12, rifamycin SV, The metabolism of Irinotecan can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Irinotecan can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The metabolism of Irinotecan can be decreased when combined with Risperidone.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Irinotecan.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Ropivacaine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Irinotecan.]
[A04AD12, aprepitant, The metabolism of Irinotecan can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Irinotecan.]
[J05AE07, fosamprenavir, The metabolism of Irinotecan can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be decreased when combined with Irinotecan.]
[C02KX02, ambrisentan, The excretion of Ambrisentan can be decreased when combined with Irinotecan.]
[C01EB18, ranolazine, The metabolism of Irinotecan can be decreased when combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be decreased when combined with Irinotecan.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Irinotecan.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Irinotecan.]
[L01DB01, doxorubicin, The metabolism of Irinotecan can be decreased when combined with Doxorubicin.]
[N06AB06, sertraline, The metabolism of Irinotecan can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The metabolism of Sevoflurane can be decreased when combined with Irinotecan.]
[C10AA01, simvastatin, The metabolism of Irinotecan can be increased when combined with Simvastatin.]
[N02CC01, sumatriptan, The excretion of Sumatriptan can be decreased when combined with Irinotecan.]
[V04CX07, edrophonium, Edrophonium may increase the neuromuscular blocking activities of Irinotecan.]
[H01AA01, corticotropin, The metabolism of Irinotecan can be increased when combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Irinotecan is combined with Temozolomide.]
[D01BA02, terbinafine, The metabolism of Irinotecan can be increased when combined with Terbinafine.]
[C09AA02, enalapril, The excretion of Enalapril can be decreased when combined with Irinotecan.]
[N03AX11, topiramate, The metabolism of Irinotecan can be increased when combined with Topiramate.]
[C03CA04, torsemide, The excretion of Torasemide can be decreased when combined with Irinotecan.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Irinotecan.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Irinotecan is combined with Trilostane.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Irinotecan is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Irinotecan.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Irinotecan.]
[S01FB02, ephedrine, The serum concentration of Ephedrine can be increased when it is combined with Irinotecan.]
[S01GX10, epinastine, The metabolism of Irinotecan can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Irinotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA12, mepirodipine, The metabolism of Irinotecan can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Irinotecan can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Irinotecan.]
[N03AX15, zonisamide, The metabolism of Zonisamide can be decreased when combined with Irinotecan.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Irinotecan.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Irinotecan is combined with Carboplatin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Irinotecan.]
[N02CA02, ergotamine, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of neutropenia can be increased when Valproic acid is combined with Irinotecan.]
[S01AA17, erythromycin, The metabolism of Irinotecan can be decreased when combined with Erythromycin.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), The excretion of Conjugated estrogens can be decreased when combined with Irinotecan.]
[J04AK02, ethambutol, The metabolism of Irinotecan can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The metabolism of Irinotecan can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Irinotecan can be increased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Irinotecan can be increased when combined with Ethinylestradiol.]
[N04AA05, profenamine, Profenamine may increase the neuromuscular blocking activities of Irinotecan.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Irinotecan.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Irinotecan.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Irinotecan.]
[A02BA04, nizatidine, Nizatidine may increase the neuromuscular blocking activities of Irinotecan.]
[R06AX11, astemizole, The metabolism of Irinotecan can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Terfenadine.]
[N06AX12, bupropion, The metabolism of Bupropion can be decreased when combined with Irinotecan.]
[N06AB08, fluvoxamine, The metabolism of Irinotecan can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Irinotecan.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, The risk or severity of neutropenia can be increased when Sodium aurothiomalate is combined with Irinotecan.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Irinotecan.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Irinotecan.]
[P02CA03, albendazole, The metabolism of Irinotecan can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Felodipine can be decreased when combined with Irinotecan.]
[N03AX26, fenfluramine, The metabolism of Irinotecan can be decreased when combined with Fenfluramine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Irinotecan.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Irinotecan.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Irinotecan.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Irinotecan.]
[J01CF05, floxacillin, The metabolism of Irinotecan can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Irinotecan can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Irinotecan.]
[N05CD03, flunitrazepam, The risk or severity of neutropenia can be increased when Flunitrazepam is combined with Irinotecan.]
[D07AC08, fluocinonide, The metabolism of Irinotecan can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Irinotecan can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Irinotecan can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Irinotecan.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Irinotecan.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Irinotecan.]
[N06AB03, fluoxetine, The metabolism of Irinotecan can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Irinotecan.]
[S01BC04, flurbiprofen, The risk or severity of neutropenia can be increased when Flurbiprofen is combined with Irinotecan.]
[L02BB01, flutamide, The metabolism of Irinotecan can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Irinotecan.]
[J05AE10, darunavir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Darunavir.]
[N06DA04, galantamine, Galantamine may increase the neuromuscular blocking activities of Irinotecan.]
[N03AA04, barbexaclone, The metabolism of Irinotecan can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The risk or severity of neutropenia can be increased when Gemfibrozil is combined with Irinotecan.]
[L01EA02, dasatinib, The metabolism of Irinotecan can be decreased when combined with Dasatinib.]
[J05AG04, etravirine, The metabolism of Irinotecan can be increased when combined with Etravirine.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be decreased when combined with Irinotecan.]
[L01EH01, lapatinib, The metabolism of Irinotecan can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Irinotecan can be decreased when combined with Glyburide.]
[C02CA04, doxazosin, The metabolism of Irinotecan can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of neutropenia can be increased when Sorafenib is combined with Irinotecan.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Fluindione is combined with Irinotecan.]
[D01BA01, griseofulvin, The metabolism of Irinotecan can be increased when combined with Griseofulvin.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Irinotecan.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Irinotecan.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Irinotecan.]
[N05AH04, quetiapine, The metabolism of Quetiapine can be decreased when combined with Irinotecan.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Antilymphocyte immunoglobulin (horse).]
[M01AG01, mefenamic acid, The metabolism of Irinotecan can be decreased when combined with Mefenamic acid.]
[R03BA09, fluticasone furoate, The metabolism of Irinotecan can be increased when combined with Fluticasone furoate.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Irinotecan.]
[C09CA01, losartan, The metabolism of Irinotecan can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Irinotecan.]
[G03DC01, allylestrenol, The metabolism of Irinotecan can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The excretion of Mesalazine can be decreased when combined with Irinotecan.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Irinotecan.]
[J05AG01, nevirapine, The metabolism of Irinotecan can be increased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Irinotecan can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Irinotecan.]
[C02DB02, hydralazine, The metabolism of Irinotecan can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Irinotecan.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Irinotecan.]
[S02BA01, hydrocortisone, The metabolism of Irinotecan can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Irinotecan.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Irinotecan is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The metabolism of Irinotecan can be decreased when combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Irinotecan can be increased when combined with Rifabutin.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Irinotecan.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Irinotecan is combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Irinotecan can be increased when combined with Ifosfamide.]
[N06AA02, imipramine, The metabolism of Irinotecan can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Irinotecan can be increased when combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Irinotecan is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Topotecan.]
[S01BC01, indomethacin, The risk or severity of neutropenia can be increased when Indomethacin is combined with Irinotecan.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Irinotecan.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Irinotecan.]
[N06AX17, milnacipran, The metabolism of Irinotecan can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Articaine.]
[N05BA12, alprazolam, The metabolism of Irinotecan can be decreased when combined with Alprazolam.]
[C10AA06, cerivastatin, The metabolism of Irinotecan can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Anagrelide is combined with Irinotecan.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Irinotecan.]
[N01AB06, isoflurane, The metabolism of Irinotecan can be decreased when combined with Isoflurane.]
[S01EB07, isoflurophate, Isoflurophate may increase the neuromuscular blocking activities of Irinotecan.]
[J04AC01, isoniazid, The metabolism of Irinotecan can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, Isoprenaline may increase the neuromuscular blocking activities of Irinotecan.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Irinotecan.]
[L04AC07, tocilizumab, The metabolism of Irinotecan can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the neuromuscular blocking activities of Irinotecan.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Irinotecan.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Irinotecan.]
[J02AB02, ketoconazole, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Ketoconazole.]
[V03AC03, deferasirox, The risk or severity of neutropenia can be increased when Deferasirox is combined with Irinotecan.]
[L04AA24, abatacept, The metabolism of Irinotecan can be increased when combined with Abatacept.]
[N07AA30, ambenonium, Ambenonium may increase the neuromuscular blocking activities of Irinotecan.]
[N03AX18, lacosamide, The metabolism of Irinotecan can be decreased when combined with Lacosamide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Irinotecan.]
[G03AD01, levonorgestrel, The metabolism of Irinotecan can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Lidocaine.]
[N06BA13, armodafinil, The metabolism of Irinotecan can be increased when combined with Armodafinil.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Lomustine.]
[C10AA02, lovastatin, The metabolism of Irinotecan can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Irinotecan.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Irinotecan is combined with Pralatrexate.]
[L01EA03, nilotinib, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Mechlorethamine.]
[P01BC02, mefloquine, Mefloquine may increase the neuromuscular blocking activities of Irinotecan.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Irinotecan.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Irinotecan.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Irinotecan.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Melphalan.]
[N06DX01, memantine, The metabolism of Irinotecan can be decreased when combined with Memantine.]
[N02AB02, meperidine, The metabolism of Irinotecan can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Irinotecan can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Irinotecan can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Irinotecan can be increased when combined with Aminoglutethimide.]
[N05AX13, paliperidone, The metabolism of Paliperidone can be decreased when combined with Irinotecan.]
[H01CB03, lanreotide, The metabolism of Irinotecan can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Irinotecan can be decreased when combined with Methadone.]
[H03BB02, methimazole, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Irinotecan.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Irinotecan.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Irinotecan.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Irinotecan.]
[V04CG05, methylene blue, The metabolism of Irinotecan can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Irinotecan can be decreased when combined with Methylergometrine.]
[H02AB04, methylprednisolone, The metabolism of Irinotecan can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Irinotecan can be increased when combined with Rufinamide.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Irinotecan.]
[N02CA04, methysergide, The metabolism of Irinotecan can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, Metoclopramide may increase the neuromuscular blocking activities of Irinotecan.]
[P01AB01, metronidazole, The metabolism of Irinotecan can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Irinotecan can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Irinotecan can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Irinotecan.]
[S02AA13, miconazole, The metabolism of Irinotecan can be decreased when combined with Miconazole.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Irinotecan.]
[N05CD08, midazolam, The metabolism of Irinotecan can be decreased when combined with Midazolam.]
[G03XB01, mifepristone, The metabolism of Irinotecan can be increased when combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Irinotecan.]
[C09CA03, valsartan, The excretion of Valsartan can be decreased when combined with Irinotecan.]
[J01FA11, miocamycin, The metabolism of Irinotecan can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Irinotecan can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Irinotecan is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The metabolism of Irinotecan can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of neutropenia can be increased when Amitriptyline is combined with Irinotecan.]
[L04AB05, certolizumab pegol, The metabolism of Irinotecan can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The risk or severity of neutropenia can be increased when Eltrombopag is combined with Irinotecan.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of neutropenia can be increased when Pazopanib is combined with Irinotecan.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Irinotecan is combined with Mycophenolic acid.]
[N05CA02, amobarbital, The metabolism of Irinotecan can be increased when combined with Amobarbital.]
[G03XC01, raloxifene, The metabolism of Irinotecan can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The metabolism of Irinotecan can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Irinotecan.]
[J01CF06, nafcillin, The metabolism of Irinotecan can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Naloxone.]
[L04AC03, anakinra, The metabolism of Irinotecan can be increased when combined with Anakinra.]
[A10BG01, troglitazone, The metabolism of Irinotecan can be increased when combined with Troglitazone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Irinotecan.]
[L01CD02, docetaxel, The metabolism of Irinotecan can be decreased when combined with Docetaxel.]
[A10BX02, repaglinide, The excretion of Repaglinide can be decreased when combined with Irinotecan.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Irinotecan.]
[S01EB06, neostigmine, Neostigmine may increase the neuromuscular blocking activities of Irinotecan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Irinotecan.]
[N06AX23, desvenlafaxine, The metabolism of Irinotecan can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Irinotecan can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Irinotecan.]
[C10AD02, niacin, The metabolism of Irinotecan can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Irinotecan can be decreased when combined with Nicardipine.]
[N07BA01, nicotine, The metabolism of Irinotecan can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Irinotecan.]
[M02AA17, niflumic acid, The metabolism of Irinotecan can be decreased when combined with Niflumic acid.]
[C08CA07, nisoldipine, The metabolism of Irinotecan can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be decreased when combined with Irinotecan.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be decreased when combined with Irinotecan.]
[G03DC02, norethindrone, The metabolism of Irinotecan can be decreased when combined with Norethisterone.]
[C02KX01, bosentan, The metabolism of Irinotecan can be increased when combined with Bosentan.]
[R05DA07, noscapine, The metabolism of Irinotecan can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Irinotecan.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Irinotecan.]
[H01CB02, octreotide, The serum concentration of Irinotecan can be increased when it is combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Irinotecan can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Irinotecan can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Irinotecan can be increased when combined with Omeprazole.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Irinotecan.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Irinotecan.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Irinotecan.]
[N02AA05, oxycodone, The metabolism of Irinotecan can be decreased when combined with Oxycodone.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Irinotecan.]
[M03AC01, pancuronium, Pancuronium may increase the neuromuscular blocking activities of Irinotecan.]
[H02AB05, paramethasone, The metabolism of Irinotecan can be increased when combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Penicillamine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Irinotecan.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Irinotecan.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Irinotecan.]
[N05CA01, pentobarbital, The metabolism of Irinotecan can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Irinotecan.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Pentoxifylline is combined with Irinotecan.]
[C08EX02, perhexiline, The metabolism of Perhexiline can be decreased when combined with Irinotecan.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Irinotecan.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Irinotecan.]
[N03AA02, phenobarbital, The metabolism of Irinotecan can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Phenprocoumon is combined with Irinotecan.]
[M02AA01, phenylbutazone, The metabolism of Irinotecan can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Irinotecan can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Irinotecan can be increased when combined with Golimumab.]
[V03AB19, physostigmine, Physostigmine may increase the neuromuscular blocking activities of Irinotecan.]
[L02BB03, bicalutamide, The metabolism of Irinotecan can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The metabolism of Irinotecan can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Irinotecan.]
[C10AA05, atorvastatin, The excretion of Atorvastatin can be decreased when combined with Irinotecan.]
[J05AE01, saquinavir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Saquinavir.]
[J05AG02, delavirdine, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irinotecan can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Irinotecan.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Irinotecan.]
[L04AC08, canakinumab, The metabolism of Irinotecan can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Irinotecan.]
[J05AE03, ritonavir, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Irinotecan.]
[C10AA08, pitavastatin, The excretion of Pitavastatin can be decreased when combined with Irinotecan.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Irinotecan.]
[S03BA02, prednisolone, The metabolism of Irinotecan can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Irinotecan.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Irinotecan can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Irinotecan can be increased when combined with Primidone.]
[M04AB01, probenecid, The risk or severity of neutropenia can be increased when Probenecid is combined with Irinotecan.]
[C01BA02, procainamide, Procainamide may increase the neuromuscular blocking activities of Irinotecan.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Irinotecan can be decreased when combined with Fenofibrate.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Irinotecan which could result in a higher serum level.]
[R06AD02, promethazine, The metabolism of Promethazine can be decreased when combined with Irinotecan.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Irinotecan.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Irinotecan.]
[N01AX10, propofol, The risk or severity of neutropenia can be increased when Propofol is combined with Irinotecan.]
[N02AC04, propoxyphene, The metabolism of Irinotecan can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Irinotecan can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Irinotecan.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Irinotecan.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Irinotecan.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Irinotecan.]
[N07AA02, pyridostigmine, Pyridostigmine may increase the neuromuscular blocking activities of Irinotecan.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Irinotecan.]
[C01BA01, quinidine, The metabolism of Irinotecan can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Irinotecan can be increased when combined with Quinine.]
[C02AA02, reserpine, The metabolism of Irinotecan can be increased when combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Irinotecan can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Irinotecan can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Irinotecan is combined with Sulfasalazine.]
[N05CA06, secobarbital, The metabolism of Irinotecan can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Irinotecan.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Irinotecan is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Irinotecan.]
[H01CB01, somatostatin, The metabolism of Irinotecan can be decreased when combined with Somatostatin.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Irinotecan.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Irinotecan.]
[D07AB02, hydrocortisone butyrate, The metabolism of Irinotecan can be increased when combined with Hydrocortisone butyrate.]
[H02CA04, levoketoconazole, The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Levoketoconazole.]
[C08DA01, verapamil, Irinotecan - CYP3A4 inhibitors]
[J05AE02, indinavir, Irinotecan - CYP3A4 inhibitors]
[J02AC03, voriconazole, Irinotecan - CYP3A4 inhibitors]
[J05AE04, nelfinavir, Irinotecan - CYP3A4 inhibitors]
[J05AE09, tipranavir, Irinotecan - CYP3A4 inhibitors]
[J01FA09, clarithromycin, Irinotecan - CYP3A4 inhibitors]
[J05AE05, amprenavir, Irinotecan - CYP3A4 inhibitors]
[A02BA01, cimetidine, Irinotecan - CYP3A4 inhibitors]
[J01FA15, telithromycin, Irinotecan - CYP3A4 inhibitors]
[J02AC02, itraconazole, Irinotecan - CYP3A4 inhibitors]
[N06AX06, nefazodone, Irinotecan - CYP3A4 inhibitors]
[J05AE08, atazanavir, Irinotecan - CYP3A4 inhibitors]
[C08DB01, diltiazem, Irinotecan - CYP3A4 inhibitors]
[A04AD12, aprepitant, Irinotecan - CYP3A4 inhibitors]
[J05AE07, fosamprenavir, Irinotecan - CYP3A4 inhibitors]
[S01AA17, erythromycin, Irinotecan - CYP3A4 inhibitors]
[J02AC01, fluconazole, Irinotecan - CYP3A4 inhibitors]
[J05AE10, darunavir, Irinotecan - CYP3A4 inhibitors]
[J02AB02, ketoconazole, Irinotecan - CYP3A4 inhibitors]
[C01BD01, amiodarone, Irinotecan - CYP3A4 inhibitors]
[J05AE01, saquinavir, Irinotecan - CYP3A4 inhibitors]
[J05AE03, ritonavir, Irinotecan - CYP3A4 inhibitors]
